AOD-9604 for Fat Loss: Does the Evidence Hold Up?

AOD-9604 is sold as the "fat-burning fragment" of growth hormone — a peptide that supposedly strips fat without any of growth hormone's effects on blood sugar or tissue growth. It is one of the most aggressively marketed weight-loss peptides on the research-chemical market, and the pitch sounds almost too clean: all of growth hormone's fat-melting power, none of its baggage. The problem is that the single most important fact about AOD-9604 is the one the marketing never mentions — when it was actually tested in a large trial of people with obesity, it did not beat a placebo. This article separates the real (and genuinely interesting) animal science from a human result that quietly ended its development.

The honest headline first: AOD-9604's fat-loss story is built on rodent studies. Its lipolytic, weight-reducing effects are well documented in obese mice, but its development program in humans did not produce a drug — the company's large clinical trial reportedly failed to show meaningful weight loss over placebo, and AOD-9604 was never approved as a weight-loss medicine anywhere. It is an unapproved research chemical, it is on the WADA radar in tested sport, and the grey-market supply carries the usual purity and contamination risks. Hold that frame against every promising mouse study below.

What AOD-9604 Actually Is

Human growth hormone (hGH) is a 191-amino-acid protein with many jobs — it raises IGF-1, builds tissue, and, separately, promotes the breakdown of fat (lipolysis). Decades ago, researchers asked whether the fat-burning action could be isolated from the rest. They found that the lipolytic activity of growth hormone is concentrated in a small region near the C-terminal end of the molecule, and that a synthetic fragment corresponding roughly to amino acids 176–191 retained the fat-metabolizing effect while shedding most of the rest¹. AOD-9604 ("Anti-Obesity Drug 9604") is a modified version of that hGH(177–191) fragment.

The selling point is mechanistic elegance: in the lab, AOD-9604 reproduced growth hormone's effects on fat metabolism — stimulating lipolysis and inhibiting lipogenesis (fat storage) — without the growth-promoting, IGF-1-raising, blood-sugar-affecting actions of the full hormone¹². On paper, that is exactly what a clean fat-loss drug would look like. The question is whether it translates from mouse adipocytes to a human standing on a scale.

The Animal Evidence — Real, and Genuinely Promising

This is where AOD-9604's case is strongest, and it deserves a fair hearing. In obese mice, chronic treatment with AOD-9604 produced real, measurable changes in fat metabolism. One study showed that giving obese mice the modified C-terminal hGH fragment increased fat oxidation and reduced body weight³. A companion line of work compared AOD-9604 directly against full-length growth hormone and reported that the fragment reduced body weight and improved lipid metabolism in obese mice after chronic dosing — without the unwanted insulin-resistance signal that full growth hormone can carry⁴.

The mechanistic studies fill in the "how": AOD-9604 stimulated lipolysis (fat breakdown) and inhibited lipogenesis (fat synthesis) in fat cells, and did so by engaging fat-metabolism pathways rather than the classical growth-hormone-receptor growth signaling¹². Taken together, the rodent and cell-culture record is coherent: in mice, AOD-9604 behaves like a targeted fat-metabolism agent that lowers body weight. That is a legitimate, interesting preclinical result.

But notice the species line running through every one of those findings: mice, and cells in dishes. A weight-loss effect in an obese mouse is a hypothesis about humans, not proof — and weight-loss research is littered with compounds that melted fat off rodents and then did nothing in people. AOD-9604, it turns out, is one of them.

The Human Trials — Where the Story Falls Apart

This is the part the marketing skips entirely. AOD-9604 was not a vague idea that never got tested — it was developed as a serious clinical drug candidate by an Australian biotech (Metabolic Pharmaceuticals) and taken into human obesity trials in the 2000s. Reviews of the obesity-drug pipeline from that era list AOD-9604 among the compounds in active clinical development for weight management⁵⁶⁷. It was a real program with real money behind it.

And then it failed to deliver. The pivotal human result — a large, placebo-controlled obesity trial running into hundreds of participants — did not show the clinically meaningful weight loss over placebo that the rodent data had promised. The company did not advance AOD-9604 to approval as a weight-loss drug, and the obesity development program was discontinued. That trial outcome is the single most decisive piece of evidence about AOD-9604 for fat loss in humans, and it points the wrong way for the marketing.

An important honesty caveat about that trial: its full results were largely communicated through the company and pipeline-review channels rather than published as a standalone peer-reviewed randomized-controlled-trial paper indexed in the medical literature. So the most rigorous public claim we can make is narrow but firm — AOD-9604 has no published, peer-reviewed human trial demonstrating it produces meaningful fat loss, and the clinical program built to prove exactly that was abandoned. When a drug's own developer runs the trial and then walks away, that absence is not a neutral gap; it is a result.

"But It's in Other Products Now" — Read the Fine Print

Defenders of AOD-9604 point out that it later resurfaced in other contexts. Two are worth addressing honestly, because both are real but neither rescues the fat-loss claim.

First, after the obesity program ended, AOD-9604 was explored for a completely different use: joint and cartilage repair. A rabbit study found that intra-articular injection of AOD-9604, with or without hyaluronic acid, had effects in an osteoarthritis model⁸. That is a legitimate (if early, animal-only) line of research — but it is about joints, not fat loss, and it does nothing to resurrect the weight-loss case.

Second, AOD-9604 has appeared in some markets framed around food/supplement use after toxicology review. That regulatory framing speaks only to whether a low oral dose appeared safe in testing — it is not evidence that the peptide works for fat loss. Safe-and-useless is a perfectly ordinary outcome, and conflating "passed a safety review" with "proven to burn fat" is exactly the sleight of hand the marketing relies on. The same evidence-first standard runs through our pillar on peptides for recovery and healing and our broader review of peptides for muscle growth, where mechanism-versus-proof is the recurring theme.

The Anti-Doping and Legal Reality

Even setting the evidence aside, AOD-9604's status should give a tested athlete pause. As a growth-hormone fragment, it sits squarely in the category anti-doping science watches closely, and dedicated analytical methods to detect AOD-9604 in doping-control samples have been developed and published⁹¹⁰ — the existence of those assays tells you regulators treat it as a substance of concern. Seizures of unapproved AOD-9604 preparations by national authorities have also been documented, underscoring its grey-market status¹¹. We cover the wider picture in our guide to whether GH peptides are safe and legal for athletes.

It is also not an approved weight-loss drug. No regulator has approved AOD-9604 as a medicine for obesity or fat loss. Practically all of it on the consumer market is sold "for research use only" by grey-market vendors — which means you cannot verify identity, purity, dose, or sterility of what is in the vial. That is the same unregulated-supply problem that haunts the entire research-peptide category, and it applies in full force here.

How It Compares to Things That Actually Move the Needle

It is worth situating AOD-9604 against the GH-axis peptides athletes more commonly reach for. Growth-hormone secretagogues like MK-677 (ibutamoren) genuinely and reliably raise growth hormone and IGF-1 — that part is real, even if the body-composition payoff is oversold — and we walk through that evidence in our MK-677 (ibutamoren) review. AOD-9604 is a different proposition: it was specifically engineered not to touch IGF-1 or the growth axis, and to act only on fat metabolism. That is elegant in theory, but the human trial that was supposed to validate it came up empty. So the comparison is stark — a peptide that demonstrably changes a blood marker but may not change your physique, versus a peptide that demonstrably changed fat in mice but failed to change the scale in people.

Bottom Line

AOD-9604 has a real and interesting preclinical record: in obese mice, the growth-hormone fragment increased fat oxidation, reduced body weight, and acted on fat-metabolism pathways without the growth-promoting effects of full growth hormone. If mouse studies decided things, it would be a promising fat-loss agent. But they don't — and the one place AOD-9604's promise had to show up, a large human obesity trial run by its own developer, it reportedly failed to beat placebo, and the program was abandoned. There is no published, peer-reviewed human trial showing it produces meaningful fat loss.

The honest position is not "AOD-9604 is a scam" and not "AOD-9604 melts fat." It is this: the mouse science was a reason to run human trials, the human trials were run, and they did not deliver a weight-loss drug. Layered on top of that are the familiar hard facts — it is unapproved, it is on the anti-doping radar, and the grey-market supply is unreliable. For where the genuinely evidence-backed recovery peptides sit, see our ranking of the best peptides for recovery and healing and our guide to vetted recovery peptide providers.